In a public effort to bring down prescription drug prices, the Biden administration plans to use the government’s “march-in” authority to sever some pharmaceutical drug patent protections. By setting aside patents on discoveries that relied on some amount of government funding, we would presumably see more generic, lower-cost versions of popular prescription medicines. This election-season policymaking may deliver lower prices to some people, but the resulting market chaos could be harmful to our health. Drug price increases covered by Medicare have exceeded inflation’s pace since 2019. Biden,…